Aligos Therapeutics, Inc. Balance Sheet
ALGS|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Aligos Therapeutics, Inc. had $89M in total assets and $54M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.3M | $37.0M | $135.7M | $81.3M | $186.8M | $220.4M |
| Current Assets | $82.9M | $62.1M | $141.1M | $133.5M | $204.4M | $250.0M |
| PP&E (Net) | $1.9M | $2.4M | $3.3M | $4.8M | $6.2M | $8.0M |
| Total Assets | $88.5M | $70.1M | $151.5M | $146.7M | $235.4M | $265.3M |
| Current Liabilities | $21.2M | $21.7M | $23.9M | $33.1M | $39.0M | $30.3M |
| Shareholders' Equity | $53.5M | -$29.0M | $103.9M | $184.7M | $220.0M | -$64.9M |